143 related articles for article (PubMed ID: 16810202)
21. Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia.
Diamanti P; Cox CV; Moppett JP; Blair A
Blood; 2013 Feb; 121(8):1384-93. PubMed ID: 23264600
[TBL] [Abstract][Full Text] [Related]
22. OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
Tomkinson B; Bendele R; Giles FJ; Brown E; Gray A; Hart K; LeRay JD; Meyer D; Pelanne M; Emerson DL
Leuk Res; 2003 Nov; 27(11):1039-50. PubMed ID: 12859997
[TBL] [Abstract][Full Text] [Related]
23. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
Juarez J; Dela Pena A; Baraz R; Hewson J; Khoo M; Cisterne A; Fricker S; Fujii N; Bradstock KF; Bendall LJ
Leukemia; 2007 Jun; 21(6):1249-57. PubMed ID: 17410186
[TBL] [Abstract][Full Text] [Related]
24. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
Liem NL; Papa RA; Milross CG; Schmid MA; Tajbakhsh M; Choi S; Ramirez CD; Rice AM; Haber M; Norris MD; MacKenzie KL; Lock RB
Blood; 2004 May; 103(10):3905-14. PubMed ID: 14764536
[TBL] [Abstract][Full Text] [Related]
25. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
Kinjyo I; Matlawska-Wasowska K; Chen X; Monks NR; Burke P; Winter SS; Wilson BS
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449314
[TBL] [Abstract][Full Text] [Related]
27. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
28. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
29. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease.
Lock RB; Liem NL; Papa RA
Methods Mol Med; 2005; 111():323-34. PubMed ID: 15911988
[TBL] [Abstract][Full Text] [Related]
30. Vorinostat approved for rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
[No Abstract] [Full Text] [Related]
31. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
32. Amlexanox Downregulates S100A6 to Sensitize
Tamai H; Yamaguchi H; Miyake K; Takatori M; Kitano T; Yamanaka S; Yui S; Fukunaga K; Nakayama K; Inokuchi K
Cancer Res; 2017 Aug; 77(16):4426-4433. PubMed ID: 28646023
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
34. Successful engraftment by leukemia initiating cells in adult acute lymphoblastic leukemia after direct intrahepatic injection into unconditioned newborn NOD/SCID mice.
Cheung AM; Fung TK; Fan AK; Wan TS; Chow HC; Leung JC; Chan LY; Kwong YL; Liang R; Leung AY
Exp Hematol; 2010 Jan; 38(1):3-10. PubMed ID: 19837128
[TBL] [Abstract][Full Text] [Related]
35. Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia.
Schimmel KJ; Nijmeijer BA; van Schie ML; Falkenburg JH; Guchelaar HJ
Leuk Res; 2007 Nov; 31(11):1545-51. PubMed ID: 17459472
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Leclerc GJ; Mou C; Leclerc GM; Mian AM; Barredo JC
Leukemia; 2010 Mar; 24(3):552-62. PubMed ID: 20072153
[TBL] [Abstract][Full Text] [Related]
37. [Progress in cancer treatment with histone deacetylase inhibitor].
Dong M; Hu XS; Chen SS; Xing PY; Feng FY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):481-5. PubMed ID: 24257296
[No Abstract] [Full Text] [Related]
38. Clonal evolution of immunoglobulin heavy chain rearrangements in childhood B-precursor acute lymphoblastic leukemia after engraftment in SCID mice.
Steenbergen EJ; Verhagen OJ; Nibbering CP; van den Berg H; van Leeuwen EF; Behrendt H; von dem Borne AE; van der Schoot CE
Leukemia; 1996 Sep; 10(9):1471-8. PubMed ID: 8751465
[TBL] [Abstract][Full Text] [Related]
39. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
40. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
